Nevro (NVRO) Set to Announce Quarterly Earnings on Thursday

Nevro (NYSE:NVRO) will post its quarterly earnings results after the market closes on Thursday, February 22nd. Analysts expect Nevro to post earnings of ($0.14) per share for the quarter.

Nevro (NVRO) opened at $79.95 on Wednesday. Nevro has a 52 week low of $65.00 and a 52 week high of $99.63. The company has a quick ratio of 6.81, a current ratio of 8.78 and a debt-to-equity ratio of 0.59. The firm has a market cap of $2,370.00, a price-to-earnings ratio of -55.14 and a beta of -0.59.

Several equities analysts recently weighed in on the stock. ValuEngine cut shares of Nevro from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. BMO Capital Markets reissued a “buy” rating and issued a $100.00 target price on shares of Nevro in a research note on Thursday, December 14th. BidaskClub cut shares of Nevro from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. TheStreet raised shares of Nevro from a “d+” rating to a “c-” rating in a research note on Monday, November 6th. Finally, Canaccord Genuity decreased their target price on shares of Nevro from $120.00 to $110.00 and set a “buy” rating for the company in a research note on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. Nevro presently has an average rating of “Hold” and an average target price of $99.25.

WARNING: “Nevro (NVRO) Set to Announce Quarterly Earnings on Thursday” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2018/02/21/nevro-nvro-set-to-announce-quarterly-earnings-on-thursday.html.

Nevro Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Earnings History for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply